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Background: Although in vitro breast cancer models have demonstrated a role for protein kinase C (PKC) a
and d isoforms in endocrine insensitivity and resistance respectively, there is currently little clinical evidence to
support these observations.
Aims: To define the pattern of PKC a and d expression using breast cancer cell lines, with and without
endocrine resistance, and also breast cancer samples, where expression can be correlated with
clinicopathological and endocrine therapy outcome data.
Methods: PKC isoform expression was examined in tamoxifen responsive, oestrogen receptor positive (ER+),
ER+ acquired tamoxifen resistant (TAM-R) and oestrogen receptor negative (ER2) cell lines by western blotting
and immunocytochemical analysis. PKC isoform expression was then examined by immunohistochemistry in
archival breast cancer specimens from primary breast cancer patients with known clinical outcome in relation
to endocrine response and survival on therapy.
Results: ER+ breast cancer cell lines expressed considerable PKC-d but barely detectable levels of PKC-a,
whereas ER2 cell lines expressed PKC-a but little PKC-d. ER+ acquired TAM-R cell lines expressed substantial
levels of both PKC-a and d. In clinical samples, high PKC-d expression correlated to endocrine responsiveness
whereas PKC-a expression correlated to ER negativity. PKC-d was an independent predictor of duration of
response to therapy. Patients showing a PKC-d+/PKC-a2 phenotype had a six times longer endocrine
response than patients with the PKC-d+/ PKC-a+ phenotype (equating to tamoxifen resistance in vitro).
Conclusions: Levels of PKC-a and d expression appear to be indicative of response to anti-oestrogen therapy
and could be useful in predicting a patient’s suitability for endocrine therapy.
A
nti-hormone therapies such as tamoxifen are widely used
to treat breast cancer patients.1 A small but significant
number of patients receiving tamoxifen however will not
respond or will develop resistance.2 3 Many mechanisms have
been suggested which may play a role in tamoxifen resistance
but the mechanisms have not yet been fully elucidated.4–7
Although rapid progress is being made in understanding the
biology of oestrogen receptor (ER) function, the only predictive
markers for endocrine therapy that currently yield sufficient
levels of evidence to be recommended for routine practice, are
ER and progesterone receptors, and to a lesser extent HER-2
status.1 Better ways of predicting which patients are suitable for
endocrine therapy would prove useful in the fight against
breast cancer. Expression of the signal transduction molecule,
protein kinase C (PKC) is increased in breast cancer models of
poor prognosis; for example, ER2 cell lines express significantly
more PKC than ER+ cell lines.8 9 However, multiple isoforms of
PKC exist, with variation in their expression profile and
mechanism of activation.10–12 We have previously shown that
ER+ MCF-7 cell lines have high PKC-d and low PKC-a
expression, whereas ER2 MDA-MB-231 cells have high PKC-
a and low PKC-d expression. A wealth of literature now support
these observations13–16 linking PKC-a expression to loss of ER
expression and adverse cellular features,13 15 and there is also
emerging data that PKC-d expression can relate to loss of
endocrine sensitivity in vitro.17 These studies did not however
investigate the effect of PKC-d expression on clinical outcome.
Moreover, a recent clinical study showed PKC-a to be decreased
in advanced breast cancer samples,18 suggesting that laboratory
observations may not translate to the clinic.
We have therefore established cell line models of tamoxifen
resistance,19 20 and used these models and well-characterised
clinical specimens21 22 with known response to endocrine
therapy, to study PKC expression. We have shown that PKC-a
and d may prove useful in predicting whether patients will
respond or not to endocrine therapy.
MATERIALS AND METHODS
Cell culture
For experimental purposes ER+ and ER2 breast cancer cell lines
were grown in phenol red-free RPMI medium supplemented
with 5% activated charcoal stripped, steroid depleted fetal calf
serum (ssFCS), 200 mM glutamine and antibiotics (10 IU/ml
penicillin, 10 mg/ml streptomycin). Acquired TAM-R cell lines
were established by culturing MCF-719 or T47D20 cells in 1027 M
4-hydroxy-tamoxifen for 6 months. These resistant cells over-
express EGF receptor,19 and have enhanced MAPK signal-
ling,20 23 24 enhanced growth characteristics,20 25 and increased
Src activity versus their parental lines.26
Western analysis
Cells were lysed in buffer (4 C˚) and acetone precipitated as
previously described.27 Protein (40 mg) was run on an 8% SDS-
PAGE gel and blotted onto membranes. Non-specific binding
was blocked with 5% non-fat milk in Tris-buffered saline (TBS;
10 mM Tris pH 7.5, 100 mM NaCl) containing 0.1% Tween-20.
Primary monoclonal antibodies (Transduction Laboratories;
a= IgG2b clone 3, d= IgG2b clone 14) were diluted according
to manufacturer’s instructions in TBS containing 1% bovine
serum albumin (BSA), and incubated with the blot for 3 hours
Abbreviations: AP-1, activator protein-1 complex; BSA, bovine serum
albumin; DAB, diamino benzidine-tetrahydrochloride; EGF, epidermal
growth factor; ER, oestrogen receptor; ERK2, extracellular signal-regulated
kinase 2; HR, hazard ratio; MAPK, mitogen activated protein kinase; NHS,
normal human serum; PBS, phosphate buffered saline; PKC, protein kinase
C; TAM-R, tamoxifen resistant; TBS, Tris buffered saline
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at 22 C˚, then overnight at 4 C˚. The membrane was washed
665 min in TBS-Tween before incubating in secondary anti-
body (mouse horseradish peroxidase conjugated, Amersham
International, 1 hour). The blot was washed 665 min in TBS-
Tween; antibody binding was detected using the SuperSignal
WEST DURA chemiluminescence system (Pierce).
Immunocytochemical examination of paraffin
embedded cells
Cells were concentrated by centrifugation (1000 g for 5 min),
then fixed in 4% formal-saline for 4 h. Fixed cells were
transferred to agar solution to form solid pellets and embedded
in paraffin-wax. Pellets were cored and assembled in triplicate
using a tissue arrayer (Beecher Instruments), forming a
composite pellet array which was sectioned (5 mm) onto
Superfrost slides before assaying as below. Using the clinically
defined HScore cut offs to define positivity, sections were
assessed for PKC-a and PKC-d expression as detailed below.
Immunohistochemical examination of clinical samples
Formal-saline (4%) fixed, paraffin-embedded breast cancer
tissue was available from 70 primary breast cancer patients,
who subsequently received systemic endocrine therapy (pri-
marily using tamoxifen) as detailed previously,21 either for
locally-advanced primary carcinoma or metastatic disease. Data
was available regarding the patients’ quality of endocrine
response (25 responders (complete, partial and static disease)
vs 45 progressive disease) assessed according to UICC criteria at
6 months, duration of endocrine response and survival time on
endocrine therapy, ER status (ie, ER2, n = 27; ER+, n = 43),
histological grade (grade 1 or 2, n = 29; grade 3, n = 40), site of
disease (locally advanced, n = 27; other sites, n = 42) and
menopausal status (premenopausal, n = 21; postmenopausal,
n = 48).
Immunostaining of clinical material (and cell pellet arrays)
was done by dewaxing paraffin sections (5 mm) in xylene and
rehydration through a decreasing alcohol concentration series.
Endogenous peroxidase activity was blocked with 3% hydrogen
peroxide solution (5 min) and antigens retrieved by previously
optimised procedures (PKC-d: 0.02% protease E in PBS at 37 C˚;
PKC-a: microwaving in citrate buffer) followed by water and
PBS rinses. Sections were blocked in normal human serum
(NHS, 20%, 15 min) and then incubated for 18 h with 16.5 mg/
ml anti-PKC-d (IgG2b clone 14, Transduction Laboratories,
preincubated with NHS for 30 min) or 2 mg/ml anti-PKC-a
(IgG1 clone 4, Upstate Biotechnology) monoclonal antibody
prepared in PBS. Sections were washed in PBS (3 min), then in
‘‘DPC’’-detergent containing buffer (265 min). Biotinylated
anti-mouse immunoglobulin (1:40 dilution in PBS containing
1% BSA) was applied for 60 min. After washing, a peroxidase-
labelled streptavidin immunodetection system was employed
(SuperSensitive Concentrated Detection Kit, Biogenex) using
DAB/hydrogen peroxide chromogen (ER-ICA kit, Abbott
Laboratories) and methyl green counterstaining.
In the absence of any obvious cut-off point for immunostain-
ing, patients were classified as PKC-a or d positive using the
median of the tumour epithelial HScore immunostaining index
for each marker,28 such that PKC-a positive = HScore .110 and
PKC-d positive = HScore .120. Relationships between PKC
status and clinicopathological parameters were examined using x2
tests. Univariate analysis of survival from initiation of therapy and
duration of endocrine response was performed using the Kaplan–
Meier method and log rank test. Multivariate analysis was
performed using a Cox proportional hazards model, controlling for
Figure 1 Western blot comparison of protein kinase C (PKC) a and d
expression in oestrogen receptor positive (ER+) cell lines (MCF-7, T47D),
their tamoxifen resistant derivative cell lines (MTR and TTR) and the ER2
MDA-MB-231 cell line (231). The resistant cell lines have increased
expression of both PKC isoforms compared to the parental cell lines.
Equality of protein loading was checked by confirming equality of b-actin
expression between samples. Figure representative of at least three
independent experiments.
Figure 2 Protein kinase C (PKC) a expression assessed by
immunocytochemical analysis of paraffin embedded cell pellets. Oestrogen
receptor positive (ER+), endocrine responsive MCF-7 and T47D cells show
low PKC-a staining and therefore a low HScore. Their tamoxifen resistant
derivatives (MTR and TTR respectively) show considerably higher levels of
PKC-a expression and correspondingly higher HScores. The ER2 MDA-
MB-231 cells show very high levels of PKC-a staining and thus HScore.
Original magnification640. Figure representative of three experiments.
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the available clinicopathological features (site of disease, tumour
grade, ER status, menopausal status). All p values were two-sided
and considered statistically significant if ,0.05.
RESULTS
PKC isoform profile in breast cancer cell lines
We examined PKC isoform expression in tamoxifen responsive
ER+ (MCF-7 and T47D) cells, acquired tamoxifen resistant sub-
lines of MCF-7 cells (MTR) and T47D (TTR) and an ER2 (MDA-
MB-231) breast cancer cell line using isoform specific anti-
bodies. The ER2 cell line expressed significant PKC-a but little
PKC-d, either by western analysis or immunocytochemistry
(figs 1, 2 and 3). The ER+ endocrine responsive cell lines
expressed abundant PKC-d but relatively low or no PKC-a
(figs 1, 2 and 3). Interestingly both acquired tamoxifen resistant
cell lines expressed increased levels of both PKC-a and PKC-d
compared to their parental cell lines (figs 1, 2 and 3).
PKC-a expression associates with poor clinical outcome
on endocrine therapy
When breast cancer samples from patients with known clinical
outcome were examined for PKC-a expression, brown immu-
nostaining was seen within the tumour epithelial cells’
cytoplasm and perinuclear region (fig 4). Staining was
heterogeneous, both within samples and between patients,
but using a median HScore of .110 (range 0–170) to define
substantial PKC-a immunopositivity versus low expression,
statistical analysis revealed an association between PKC-a and
ER status, with ER2 disease showing substantially more PKC-a
staining than ER+ tissues (table 1 and fig 4). Expression was
not significantly related to disease site, menopausal status or
grade of tumour but did correlate to quality of response as
measured at 6 months’ endocrine therapy, with high PKC-a
expression related to progressive disease (table 1). Furthermore,
univariate analysis showed a significantly shorter duration of
endocrine response in those patients whose tumours were PKC-a
positive (median duration of response: PKC-a+ 2 months, 95% CI
0.9 to 3.1; PKC-a2 6 months, 95% CI 2.7 to 9.3; p = 0.003). There
was also a significant decrease in survival time from initiation of
endocrine therapy in PKC-a positive patients (median survival:
PKC-a+ 12 months, 95% CI 2.9 to 21.1; PKC-a2 29 months, 95%
CI 22.0 to 36.1; p = 0.03). PKC-a status was not however an
independent predictor of survival on therapy (p = 0.86, HR = 0.95,
95% CI 0.5 to 1.7) or duration of response (p = 0.70, HR = 1.13,
95% CI 0.6 to 2.0) by multivariate analysis, controlling for
clinicopathological profile (including ER status).
PKC-d expression predicts for endocrine responsiveness
PKC-d immunostaining was readily detectable in the tumour
epithelial cells’ cytoplasm, but again staining was heterogeneous
Figure 3 Immunocytochemical analysis of protein kinase C (PKC) d
expression in paraffin embedded cell pellets. Oestrogen receptor negative
(ER2) MDA-MB-231 cells show very low levels of PKC-d expression and
thus HScore. PKC-d expression is much more abundant in ER+, endocrine
responsive MCF-7 and T47D cells and thus they have a higher HScore.
Their tamoxifen resistant derivatives (MTR and TTR respectively) show a
further increase in PKC-d expression, reflected by further increased
HScores. Original magnification 640. Figure representative of three
experiments.
Figure 4 Expression of protein kinase C (PKC) a in human breast cancer
samples (positive staining is brown, with methyl green nuclear
counterstaining) showing heterogeneity of staining. Representative sections
showing (A) strong PKC-a positive staining (HScore = 150) and (B) weaker
PKC-a staining (HScore = 100) within oestrogen receptor negative patients.
(C) An oestrogen receptor positive section, in this instance showing weak
PKC-a (HScore = 10) staining. (D) (i) Negative control section, treated
identically to (ii) matched positive staining section except that the control
section was incubated with normal human serum-containing diluent instead
of primary antibody. Original magnification 640.
1218 Assender, Gee, Lewis, et al
www.jclinpath.com
 group.bmj.com on April 2, 2012 - Published by jcp.bmj.comDownloaded from 
both within samples and between patients (fig 5). Using the
median HScore (.120, range 20–190) to define substantial PKC-d
immunopositivity, statistical analysis failed to reveal any associa-
tion between PKC-d and ER status (table 2). There was also no
association with site of disease, menopausal status or tumour
grade. However, a significant relationship was observed between
PKC-d status and quality of response at 6 months on endocrine
therapy, with PKC-d positivity associated with response to therapy
(table 2). This relationship was retained even after selecting for
patients with ER+ disease. Univariate analysis confirmed that
there was a trend for longer duration of endocrine response to be
Table 1 Association between PKC-a expression and clinicopathological variables for the







Negative 28 21 7 ,0.01*
Positive 42 13 29
Total 70
Site of disease 0.10
Locally advanced 27 10 17
Metastatic disease 42 24 18
Total 69
Menopausal status 0.06
Premenopausal 21 14 7
Postmenopausal 48 20 28
Total 69
Tumour grade 0.26
Grade 1 or 2 29 12 17
Grade 3 40 22 18
Total 69
Quality of response to therapy at 6 months 0.01*
CR/PR/SD 25 7 18
PD 45 27 18
Total 70
PKC, protein kinase C; ER, oestrogen receptor; CR, complete response; PR, partial response; SD, static disease; PD,
progressive disease.
*Statistically significant (p,0.05).
Figure 5 Protein kinase C (PKC) d expression in a series of breast cancer
samples (positive staining is brown, with methyl green nuclear
counterstaining) for which patient response to endocrine therapy was known.
Representative sections show (A) strong PKC-d positive staining
(HScore = 170) and (B) weak PKC-d staining (HScore = 110) within oestrogen
receptor positive patients. (C) A representative oestrogen receptor negative
section showing weak PKC-d (HScore = 52) staining. (D) Negative control
section, treated identically to (C) matched weak positive staining section
except that the control section was incubated with normal human serum-
containing diluent instead of primary antibody. Original magnification640.
Figure 6 Kaplan–Meier curves for (A) duration of endocrine response
and (B) survival from initiation of therapy. The phenotype protein kinase C
a2/d+ can be seen to have a significantly better response (p = 0.009) and
survival (p = 0.066) than any of the other phenotypes.
PKC in tamoxifen resistant breast cancer 1219
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associated with PKC-d positive tumours (median duration of
response: PKC-d+ 7 months, 95% CI 2.6 to 11.4; PKC-d2
3 months, 95% CI 1.5 to 4.5; p = 0.08). PKC-d status was however
poorly associated with survival from initiation of therapy
(p = 0.13). Controlling for clinicopathological profile, multivariate
analysis revealed that PKC-d status was a significant independent
predictor of duration of response, with PKC-d positive status
associated with a reduced risk of relapse of 47% compared to PKC-
d negative patients (p = 0.045, HR = 0.53, 95% CI 0.29 to 0.99). On
this sample set, however, it was not an effective predictor of
survival from initiation of therapy (p = 0.20, HR = 0.69, 95% CI
0.4 to 1.2).
Effect of co-isoform expression
Co-expression of PKC-d and a (PKC-d+/PKC-a+), paralleling the
phenotype seen in the TAM-R cell lines, predicted for a
particularly poor clinical outlook, with very short duration of
endocrine response and poorer survival on endocrine therapy
(fig 6). In contrast, expression of PKC-d in the absence of PKC-
a (PKC-d+/PKC-a2) appears to be beneficial, with patients
exhibiting a longer duration of response and improved survival
on endocrine therapy than patients with the other PKC isoform
combinations (fig 6; p = 0.009 for duration of response and
p = 0.066 for survival on therapy). Intriguingly, even after
selecting for ER+ patients, PKC-d+/PKC-a2 patients appeared to
have a longer duration of response than PKC-d+/PKC-a+
patients (median response time 14 months vs 6 months,
p = 0.02).
DISCUSSION
An association between PKC-a overexpression and the ER2
phenotype has previously been established in cell line models of
breast cancer.13 15 In addition, increases in growth rate,29 ERK2
expression,30 basal AP-1 activity,15 multidrug resistance,31 and
morphological changes29 32 have been shown to result from
PKC-a overexpression. Although a small clinicopathological
study (15 pairs of samples)33 showed PKC-a expression to
predict for tamoxifen treatment failure, a 46-sample study
showed a down-regulation of PKC-a expression in advanced
tumour samples.18 This study has not only confirmed the
relationship between PKC-a expression and ER negativity in
breast cancer cell lines (using ER+ MCF-7, T47D and ER2 MDA-
MB-231 cells) but also shown an association with ER2 staining
in clinical material, in a larger (70 sample) study.
Cumulatively this study and others,14 16 have shown a
correlation between ER positivity and PKC-d expression in a
variety of cell line models. Importantly we also show here a
good correlation between PKC-d expression and improved
quality and duration of endocrine response in clinical samples.
Moreover PKC-d was shown to be an independent predictor of
such response even after correcting for ER status.
Interestingly, over-expression of PKC-d in cell line and
xenograft models of breast cancer has recently been shown to
contribute to anti-oestrogen resistance,17 which would initially
appear to conflict with our findings. However, we have shown
that TAM-R cell lines have raised levels of both PKC-a and d
versus their responsive parental cells. Careful scrutiny of the
published study17 and other recent studies claiming association
between PKC-a expression and tamoxifen resistance,34 35
reveals that their tamoxifen resistant cell lines also have raised
levels of both PKC-a and d, in complete agreement with our
results. We have looked at the effect of a and d isoform co-
expression on clinical outcome, showing that co-expression of
PKC-a and d predicts for a very short duration of endocrine
response and survival on endocrine therapy, in keeping with
these being endocrine resistant patients. Although after sub-
division our sample size is small, our results are fully in keeping
with these previous studies17 34 and importantly also add to
them, indicating that it is co-expression of PKC- a and d that is
associated with endocrine resistance, both in cell line models
and more importantly in clinical samples.
Thus, knowledge of PKC isoform expression could be useful
in helping to predict patients’ endocrine responsiveness, with
expression of PKC-d in the absence of PKC-a predicting for
good endocrine response, PKC-a expression in the absence of
PKC-d associating with ER negativity, and associated endocrine
Table 2 Association between PKC-d expression and clinicopathological variables for the







Negative 28 13 15 0.77
Positive 42 21 21
Total 70
Site of disease
Locally advanced 27 12 15 0.65
Metastatic disease 42 21 21
Total 69
Menopausal status
Premenopausal 21 10 11 0.98
Postmenopausal 48 23 25
Total 69
Tumour grade
Grade 1 or 2 29 14 15 0.95
Grade 3 40 19 21
Total 69
Quality of response to therapy at 6 months
CR/PR/SD 25 17 8 0.015*
PD 45 17 28
Total 70
Endocrine response in ER+ disease
CR/PR/SD 24 16 8 0.013*
PD 18 5 13
Total 42
PKC, protein kinase C; ER, oestrogen receptor; CR, complete response; PR, partial response; SD, static disease; PD,
progressive disease.
statistically significant (p,0.05)
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insensitivity and co-expression of PKC-a with PKC-d predicting
for endocrine resistance.
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Take-home messages
N Protein kinase C (PKC) isoform expression is indicative of
a patient’s likely responsiveness to anti-oestrogen ther-
apy.
N In vitro, oestrogen receptor positive (ER+) cell lines
express PKC-d but little PKC-a, ER2 cells express PKC-a
but little d, while tamoxifen resistant cells express
increased levels of both isoforms.
N These in vitro models emulate the in vivo clinical situation,
where high PKC-d expression correlates with endocrine
responsiveness, PKC-a expression correlates with ER
negativity, and co-expression of PKC-a and d correlates
with poor endocrine response and short on-therapy
survival times.
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